The development of 5-LOX inhibitors capable of interrupting the 5-lipoxygenase axis in prostate cancer cells remains the focus of numerous investigations, and there is increasing evidence suggesting that LOX inhibition is a promising therapeutic approach in the treatment of prostate cancer [13, 14]. This evidence concerns the gene LOX and prostate carcinoma.